Filtered By:
Condition: Coronary Heart Disease
Drug: Aspirin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 48 results found since Jan 2013.

Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort
ConclusionsThe VITAL data confirmed diabetes as an important risk factor for cardiovascular events in a contemporary cohort but did not show cardiovascular benefits of aspirin in primary prevention among people with diabetes who were shown to be at higher risk of cardiovascular events.
Source: Journal of Endocrinological Investigation - June 15, 2023 Category: Endocrinology Source Type: research

Panax notoginseng preparation plus aspirin versus aspirin alone on platelet aggregation and coagulation in patients with coronary heart disease or ischemic stroke: A meta-analysis of randomized controlled trials
Conclusion: PNP combined with ASA might produce stronger antiplatelet aggregation and anticoagulation effects without increasing bleeding risk, gastrointestinal side effects, and urticaria compared with ASA alone.Systematic Review Registration:https://www.crd.york.ac.uk/PROSPERO/#recordDetails, identifier CRD42022339234.
Source: Frontiers in Pharmacology - December 7, 2022 Category: Drugs & Pharmacology Source Type: research

Elevated Levels of Serum Alkaline Phosphatase are Associated with Increased Risk of Cardiovascular Disease: A Prospective Cohort Study
CONCLUSIONS: Higher ALP levels, even within the normal range, were significantly associated with increased risks of CVD, in a dose-dependent manner. These findings suggested that regular monitoring of ALP levels may help in improving the early identification of the population at higher CVD risk.PMID:36261365 | DOI:10.5551/jat.63646
Source: Journal of Atherosclerosis and Thrombosis - October 19, 2022 Category: Cardiology Authors: Kang Liu Yanqiu Yu Yu Yuan Xuedan Xu Wenhui Lei Rundong Niu Miaoyan Shen Lue Zhou Rong Peng Qiuhong Wang Handong Yang Huan Guo Yang Ge Gang Liu Meian He Tangchun Wu Xiaomin Zhang Source Type: research

Factors affecting physician decision-making regarding antiplatelet therapy in minor ischemic stroke
ConclusionsMany factors affect doctors' decisions regarding antiplatelet therapy, especially guidelines, age, admission SBP level, and hypertensive disease.
Source: Frontiers in Neurology - September 1, 2022 Category: Neurology Source Type: research

Fatal Adverse Events of Dabigatran Combined With Aspirin in Elderly Patients: An Analysis Using Data From VigiBase
Conclusion: The fatal adverse events associated with the combined use of dabigatran and aspirin in elderly patients were mainly serious bleeding events, which often occurred within 1 month. Most of these cases had medication errors and most of the patients had multiple diseases, medications, or other conditions at the same time that increase the risk of bleeding. It is suggested that prescription of dabigatran and aspirin in elderly patients should go along with alertness for medication errors, care for correct dose or control of other bleeding risk factors, and the combined medication time should be as short as possible ...
Source: Frontiers in Pharmacology - December 22, 2021 Category: Drugs & Pharmacology Source Type: research

Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association
Circulation. 2021 Mar 29:CIR0000000000000961. doi: 10.1161/CIR.0000000000000961. Online ahead of print.ABSTRACTThis statement summarizes evidence that adverse pregnancy outcomes (APOs) such as hypertensive disorders of pregnancy, preterm delivery, gestational diabetes, small-for-gestational-age delivery, placental abruption, and pregnancy loss increase a woman's risk of developing cardiovascular disease (CVD) risk factors and of developing subsequent CVD (including fatal and nonfatal coronary heart disease, stroke, peripheral vascular disease, and heart failure). This statement highlights the importance of recognizing APOs...
Source: Circulation - March 29, 2021 Category: Cardiology Authors: Nisha I Parikh Juan M Gonzalez Cheryl A M Anderson Suzanne E Judd Kathryn M Rexrode Mark A Hlatky Erica P Gunderson Jennifer J Stuart Dhananjay Vaidya American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombos Source Type: research

Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis
AbstractThe mortality effects and risk –benefit profile of low dose rivaroxaban (2.5 mg twice daily) in patients with coronary heart disease are not completely understood. Five randomized controlled trials (26,110 patients) were selected using PubMed and Cochrane library till April 2019. The background antiplatelet therapy was aspirin in 3 trials, P2Y12 inhibitor in 1 trial, and in 1 trial 65% patients received aspirin and 35% were on dual antiplatelet therapy (DAPT). The outcomes of interest were cardiovascular mortality, all-cause mortality, myocardial infarction (MI), stroke and major bleeding events. Random effects ...
Source: Journal of Thrombosis and Thrombolysis - April 12, 2020 Category: Hematology Source Type: research

Targeting Inflammation and Immune System in Acute Myocardial Infarction.
Authors: Alwi I Abstract Over more than two decades, the concept of atherosclerosis has developed and lead to inflammatory hypothesis. Inflammation plays an important role on pathogenesis of atherothrombosis and coronary heart disease (CHD), including acute coronary syndrome (ACS). Although the management of ACS has been demonstrated to be beneficial for secondary prevention of coronary heart disease (such as using statin and aspirin) and also seemed to have positive effect on inflammation, the identification of effective management, specifically targeting inflammation, has been not been comprehensively understood....
Source: Acta medica Indonesiana - February 13, 2020 Category: Internal Medicine Tags: Acta Med Indones Source Type: research

Aspirin for the Primary Prevention of Cardiovascular Disease: A Review of the Literature and Considerations for Clinical Practice
This article reviews landmark clinical trials of aspirin in primary prevention and highlights key changes in dosing strategies and demographics.
Source: Cardiology in Review - February 6, 2020 Category: Cardiology Tags: Curbside Consult Source Type: research